Hyloris Pharmaceuticals SA (DE:52U) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hyloris Pharmaceuticals has reported positive clinical study results for its Valacyclovir Oral Suspension, showing comparable bioavailability to Valtrex tablets in Europe. With these findings, the company plans to submit regulatory applications in selected European markets by the first half of 2025. Hyloris aims to expand its market presence beyond the U.S., targeting key regions such as Europe, Canada, and Asia.
For further insights into DE:52U stock, check out TipRanks’ Stock Analysis page.